News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–72
- Matches
- 818
- Sources here
- 21
- Companies here
- 17
Active search
818 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
GeoVax Labs (GOVX) holders report 1.59% stake tied to 118,715 warrants
Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri collectively reported beneficial ownership of 118,715 shares of GeoVax Labs (GOVX) common stock through warrants. This represents a 1.59% stake based on 7,369,243 shares outstanding as of July …
Is Planet Labs The Cheapest Stock In The Space Economy?
Key Points Planet Labs’ stock has plunged more than 50% from its all-time high. It's cheaper than its peers, but investors shouldn’t ignore the red flags.10 stocks we like better than Planet Labs PBC › Planet Labs(NYSE: PL), a developer of satellite constellations, went …
Absci Corp. Earnings Call Highlights ABS-201 And Cash
Absci Corp.'s Q2 earnings call highlighted promising interim Phase I data for its flagship antibody ABS-201, showing favorable safety, tolerability, and a long half-life. The company's financial position has been significantly strengthened by a recent $100 million financing, including a $40 million strategic investment …
7,574 Shares in Astera Labs, Inc. $ALAB Bought by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. has acquired 7,574 shares of Astera Labs, Inc. (NASDAQ:ALAB) for approximately $3.66 million, marking a new position for the institutional investor. This move comes amidst Astera Labs' strong quarterly performance, with revenue increasing by 104.5% year-over-year and EPS beating analyst …
GeoVax Labs, Inc. (GOVX) holders cap ownership at 4.99% with warrants
Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC collectively reported a 4.99% beneficial ownership in GeoVax Labs, Inc. (GOVX) as of June 2026, totaling 273,657 shares derived from exercisable warrants. This stake is capped at 4.99% due to blocker provisions in additional …
GOVX: GEO-MVA targets a $1.3B vaccine market gap with expedited approval and scalable U.S. supply
GeoVax Labs, Inc. (GOVX) aims to disrupt the global MVA vaccine market with its GEO-MVA program, addressing a $1.3 billion demand through a fast-tracked regulatory process and scalable U.S. manufacturing. Additionally, the company is advancing Gedeptin® as a novel therapy for solid tumors, supported …
Citigroup Upgrades Establishment Labs to Buy From Neutral, Price Target is $92
Citigroup has upgraded its rating for Establishment Labs Holdings Inc. to 'Buy' from 'Neutral', setting a new price target of $92. This upgrade follows the company's recent Q2 2026 earnings report, where it exceeded revenue estimates and raised its full-year 2026 earnings guidance. Establishment …
Q3 EPS Estimates for Shattuck Labs Raised by HC Wainwright
HC Wainwright has raised its Q3 2026 EPS estimate for Shattuck Labs (NASDAQ:STTK) to a loss of $0.09 per share, an improvement from the previous estimate of a $0.21 loss. The firm maintained a "Buy" rating and a $14 price target, while the overall …
Proto Labs, Inc. $PRLB Position Raised by Quantinno Capital Management LP
Quantinno Capital Management LP significantly increased its stake in Proto Labs, Inc. (NYSE:PRLB) by 98.9% in the first quarter, now owning 27,716 shares valued at $1.58 million. This comes as Proto Labs reported strong quarterly earnings, beating analyst estimates with an EPS of $0.60 …
214,546 Shares in BioAge Labs, Inc. $BIOA Purchased by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP acquired a new position in BioAge Labs, Inc. (NASDAQ:BIOA), purchasing 214,546 shares valued at approximately $3.75 million, representing a 0.48% stake in the company. Other institutional investors like Geode Capital and Marshall Wace also increased their holdings. Despite reporting a …
Astera Labs, Inc. (NASDAQ:ALAB) Given Average Recommendation of "Moderate Buy" by Analysts
Analysts have issued a "Moderate Buy" rating for Astera Labs (NASDAQ:ALAB), with 13 buy recommendations and 10 hold ratings, and an average 12-month price target of $325.25. The company demonstrated strong operating momentum, with revenue up 104.5% year-over-year and EPS exceeding estimates, driven by …
VivoSim: Fiscal Q1 Earnings Snapshot
VivoSim Labs, Inc. (VIVS) reported a fiscal first-quarter loss of $1.3 million, or 25 cents per share. The San Diego-based development-stage company, which focuses on functional human tissue for research, posted revenue of $18,000 for the period.
Astera Labs Inc Stock (ALAB) Moved Up by 6.11% on Aug 12: Key Drivers Unveiled
Astera Labs Inc (ALAB) saw its stock price increase by 6.11% on August 12, driven by strong quarterly financial results that surpassed expectations and robust demand for its semiconductor connectivity solutions in AI infrastructure. Analyst upgrades and positive market sentiment surrounding AI deployment also …
Sharemaestro market context Trend signal active 52 weeks +56.7%Astera Labs (NASDAQ:ALAB) Shares Gap Up - Should You Buy?
Astera Labs (NASDAQ:ALAB) shares gapped up by 6.6% to $334.49, driven by optimism for AI connectivity products and strong financial results including 104.5% year-over-year revenue growth. Northland Securities significantly raised its earnings forecasts for the company, while AMD's Helios AI systems are anticipated to …
Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million investment and development …
ALAB Benefits From PCIe Demand: Can It Stay Ahead of Its Competitors?
Astera Labs (ALAB) is experiencing significant growth due to high demand for PCIe solutions, especially in AI infrastructure, with record revenues in Q2 2026 and strong projections for Q3. The company's diverse product portfolio and focus on next-generation technologies like PCIe 6, UALink, and …
Sharemaestro market context Trend signal active 52 weeks +56.7%Proto Labs (PRLB) Upgraded to Strong Buy: Here's Why
Proto Labs (PRLB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. The …
Sharemaestro market context Trend signal active 52 weeks +81.2%Proto Labs Inc stock hits 52-week high at 92.0 USD
Proto Labs Inc. (PRLB) shares have reached a new 52-week high of $92.00, driven by an impressive 90% total return over the past year and nearly 79% year-to-date. This growth follows strong Q2 results, exceeding analyst expectations with record revenue and adjusted earnings, and …
H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion
H.C. Wainwright has lowered its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18, while maintaining a Buy rating, following the company's Q2 2026 financial results and an expanded Phase 2b trial for its lead asset, SL-325. Despite the price target cut, the …